Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis Broadens Cardiovascular Drug Research for Mitsubishi

NEW YORK, Sept. 10-The chemical genomics company NeoGenesis has successfully identified lead compounds for Mitsubishi Pharma and will continue to develop a small molecule for its Japanese partner, the company said today.


This research builds upon a deal struck in August 2001, whereby NeoGenesis agreed to screen compounds and identify potential drugs for cardiovascular disease targets supplied by Mitsubishi.


NeoGenesis CEO Satish Jindel said that this research program was challenging, and that no small molecules had previously been identified as strong drug candidates for this target.


The company will now develop the compound through preclinical stages, he said. In return, NeoGenesis received an undisclosed milestone payment from Mitsubishi.


NeoGenesis is privately held, and based in Cambridge, Mass.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.